#Germany #CAR-T #Cologne #Cellex #ATMP

Cellex Cell Professionals Reaches 10,000 Batches Milestone

Cellex Cell Professionals has proudly announced that it has surpassed the milestone of producing 10,000 autologous batches of advanced therapy medicinal products (ATMPs). This remarkable achievement reflects the company’s expertise and dedication in the field of contract development and manufacturing for personalized cellular therapies.

The production of each batch in autologous cell therapy is custom-made for individual patients. This entails a meticulous process that includes the collection of raw materials, manufacturing, quality control, logistics, and identity chain processes, all tailored to the specific needs of each patient. Given the intricate workflows involved, reaching this milestone highlights not just the volume produced, but also the complexity and precision required in each operation.

According to Dr. Suvi Annala, Vice President of Manufacturing, “Each of these 10,000 batches was made for a specific patient. Behind each lie a coordinated chain of collection, manufacturing, analysis, and logistics that must adhere to a crucial timeline for those awaiting treatment. Everything we learn from each program with our partners directly informs the management of the next.” This statement illustrates the company's commitment not only to quantity but also to the quality and timeliness of each treatment.

Cellex’s understanding of the challenges involved in the ecosystem of cell therapies stems from its own development programs. Particularly, their CAR-T programs led to the establishment of AvenCell in 2021, where they focus on developing both autologous and allogeneic CAR-T therapies utilizing CRISPR/Cas technologies, which positions Cellex favorably with insights directly from the scientific, regulatory, and operational obstacles faced by their clinical partners.

Investments continue to be made in enhancing capabilities that meet the needs of increasingly complex cell therapy programs, including the addition of Class B clean rooms at Cellex’s facility in Cologne, Ossendorf. With these advancements, Cellex is prepared to continue its collaboration with partners, reliably providing complex cellular therapies to patients on a larger scale.

As a Contract Development and Manufacturing Organization (CDMO) specializing in cell therapies, Cellex boasts over a decade of experience in manufacturing both autologous and allogeneic products. The company supports pharmaceutical, biotech, and academic partners from preclinical through clinical development into commercial manufacturing, all while ensuring compliance with updated Good Manufacturing Practice (GMP) standards and an agile supply chain for cellular raw materials.

With this milestone, Cellex Cell Professionals not only establishes its position as a leader in the manufacturing of personalized therapies but also reinforces its commitment to advancing medical treatments that can significantly improve patient outcomes. As they move forward, the focus remains on refining processes and expanding capacity to meet the evolving demands of the healthcare landscape.

For more information, visit www.cellex.me/en.